What's hot

View all perspectives
What's Hot

It’s Not Just the Mom, It’s the Dad, Too! Dr. Jonathan Kay

Rheumatoid arthritis in either partner can affect fertility and pregnancy outcomes. Dr. Kay discusses abstract OP0210, abstract OP0212 and abstract OP0211 presented at the virtual EULAR meeting. 

Watch video →
RheumNow Podcast square

RheumNow Podcast - Best of EULAR 2021

Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.

Read more →
audience learn

EULAR 2021 - Day 3 Report

Here are a few notable presentations from this past Friday, Day 3 of the EULAR 2021 virtual meeting.

Read more →

The PsA SpA Paradox of Choice: Dr. Rachel Tate

Dr. Rachel Tate reviews Dr. Laura Coates' presentation Personalized Treatment Strategies in Psoriatic Arthritis, given at the virtual EULAR 2021 meeting. 

Watch video →

Did I Forget Something? Dr. Jonathan Kay

Dr. Jonathan Kay examines abstracts OP0216 and OP0215 that were presented at the virtual EULAR 2021 meeting. 

Watch video →

2021 GRAPPA Treatment Guidelines for Adult PsO & PsA Patients: Dr. Rachel Tate

Dr. Rachel Tate discusses the evidence-based GRAPPA treatment recommendations (abstract OP0229) presented at the virtual EULAR 2021 meeting. 

Watch video →
RheumNow Podcast square

RheumNow Podcast - EULAR 2021 & EULAR-IQ (6.4.21)

Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.

Read more →

RA and Cancer: Myth or Reality? Dr. Jonathan Kay

Dr. Jonathan Kay reviewed highlights from the "Oncorheumatology: the crossroads of cancer and musculoskeletal diseases" scientific session including abstract  OP0187, presented Thursday at the virtual EULAR 2021 meeting.

Watch video →

Psoriatic Arthritis Highlights from EULAR21: Dr. Jack Cush

Dr. Jack Cush reviews two abstracts presented at the virtual EULAR 2021 meeting: abstract OP0010 (Efficacy and Safety of Faecal Microbiota Transplantation for Active Peripheral Psoriatic Arthritis: A Randomised Sham-Controlled Trial) and abstract LB0004 (Efficacy and Safety of Secukinumab in Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis: Primary Results from a Randomised, Double-Blind, Placebo-Controlled, Treatment Withdrawal, Phase 3 Study [JUNIPERA])

Watch video →

Do Patients on Upadacitinib Need Labs? Dr. Janet Pope

Dr. Janet Pope discusses abstract OP00128, "Integrated Laboratory Abnormality Profiles of Upadacitinib with up to 4.5 Year of Exposure in Patients with Rheumatoid Arthritis Treated in the Select Phase 3 Program", presented at the virtual EULAR 2021 meeting.

Watch video →

How to Measure Success in Lupus? Dr. Kathryn Dao

Dr. Kathryn Dao discusses abstract OP0296, "The 2021 DORIS Definition of Remission in SLE - Final Recommendations From an International Task Force", presented at the virtual EULAR 2021 meeting.

Watch video →

A Triple Header of RA Plenary Abstracts: Dr. Jonathan Kay

Dr. Jonathan Kay reviews three RA abstracts from the opening plenary session at the EULAR 2021 virtual meeting: abstract OP0012; abstract OP0007; and abstract OP0006.       

Watch video →

PROs in Spa and PSA: Dr. Rachel Tate

Dr. Rachel Tate reviews two abstracts - OP0051 and OP0049 - presented at the virtual EULAR 2021 meeting.

Watch video →
      RT @MeralElRamahiMD: #EULAR2021: SpA pts w/ predominant axial phenotype tended to be HLAB27+ & have uveitis whereas

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years 5 months ago
      #EULAR2021: SpA pts w/ predominant axial phenotype tended to be HLAB27+ & have uveitis whereas those w/ predom peripheral phenotype tended to have arthritis, dactylitis, or psoriasis & fit a clinical dx of axSpA & psSpa (incl psA) respectively per this observat study. @RheumNow https://t.co/E5UTbc6Sqb
      RT @MeralElRamahiMD: #EULAR2021 bDMARD and TNF-i naive patients w/ r-axSpA without evidence of objective inflammation (n

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years 5 months ago
      #EULAR2021 bDMARD and TNF-i naive patients w/ r-axSpA without evidence of objective inflammation (normal CRP & MRI ) showed ASA40 response w/ ixekizumab @RheumNow https://t.co/5KT8A81auq
      RT @Stiddyo: #OP0089 Do you know the pain catastrophizing score #PCS ? Cross-sectional study of 1199 #RA, #PsA & #a

      Paul Studenic Stiddyo

      4 years 5 months ago
      #OP0089 Do you know the pain catastrophizing score #PCS ? Cross-sectional study of 1199 #RA, #PsA & #ax-SpA patients: Low PCS were more often in remission as high PCS in RA & ax-SpA. PCS was associated with remission rates in RA and ax-SpA, but not in PsA #EULAR2021 @RheumNow https://t.co/MYiLmPPbDN
      RT @MeralElRamahiMD: #EULAR2021: "I am an advocate for smart T2T, not a mathematical T2T approach." - Dr. Filip van den

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years 5 months ago
      #EULAR2021: "I am an advocate for smart T2T, not a mathematical T2T approach." - Dr. Filip van den Bosch @RheumNow
      RT @MeralElRamahiMD: #EULAR2021: In India, some of the JAKi are costing less than $30/mo per a EULAR participant! Dr. Fi

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years 5 months ago
      #EULAR2021: In India, some of the JAKi are costing less than $30/mo per a EULAR participant! Dr. Filip van den Bosch does not recommend using tofacitinib as a diagnostic tool for SpA over NSAIDs even if it is so cheap. @RheumNow
      RT @MeralElRamahiMD: #EULAR2021: Reduced likelihood of reaching disease remission in patients with RA or PsA who have co

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years 5 months ago
      #EULAR2021: Reduced likelihood of reaching disease remission in patients with RA or PsA who have concomitant depression and anxiety per prospective NOR-DMARD study. Social state and mental health factors play an important role in noresponse in T2T approach. @RheumNow https://t.co/Vl0Xkz2SNF
      RT @MeralElRamahiMD: #EULAR2021: Dr. Filip van den Bosch recommends the "DEER" treatment approach for SpA: Dedicated Emp

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years 5 months ago
      #EULAR2021: Dr. Filip van den Bosch recommends the "DEER" treatment approach for SpA: Dedicated Empathic and Educated Rheumatologist! @RheumNow https://t.co/W0jbGXk7q8
      RT @Stiddyo: Prof. Alten outlined the value of patient-reported outcomes for clinical practice!
      How do you collect patie

      Paul Studenic Stiddyo

      4 years 5 months ago
      Prof. Alten outlined the value of patient-reported outcomes for clinical practice! How do you collect patient-reported outcomes - PRO - in your rheumatology clinic? #EULAR2021 @RheumNow
      RT @Stiddyo: Skin fibroblasts in #CRPS: Immunohistological staining of NT3 showed higher expression in the affected vs.

      Paul Studenic Stiddyo

      4 years 5 months ago
      Skin fibroblasts in #CRPS: Immunohistological staining of NT3 showed higher expression in the affected vs. not affected side. Increasing NT3 expression <> pain increase. -->dysregulated communication of #fibroblasts with the sensory nerve fibers. #OP0085 #EULAR2021 @RheumNow
      RT @Stiddyo: #OP0049 corevitas observational registry: ax-SpA patients showed younger age, more males, greater spinal pa

      Paul Studenic Stiddyo

      4 years 5 months ago
      #OP0049 corevitas observational registry: ax-SpA patients showed younger age, more males, greater spinal pain, more exposure to cs- or bDMARD but similar fatigue and work impairment compared to ax-PsA #EULAR2021 @RheumNow
      RT @MeralElRamahiMD: #EULAR2021: If we review ASAS40 response from infliximab to tofacitinib, then there has not been mu

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years 5 months ago
      #EULAR2021: If we review ASAS40 response from infliximab to tofacitinib, then there has not been much evolution in efficacy of therapy for SpA in the past 20 yrs. This suggests we haven't been looking at the right endpoint in measuring efficacy! MDA instead! @RheumNow https://t.co/E61yb97CRN
      RT @MeralElRamahiMD: #Eular2021: There is no diagnostic criteria for nr-AxSpA, but there is a diagnostic approach that e

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years 5 months ago
      #Eular2021: There is no diagnostic criteria for nr-AxSpA, but there is a diagnostic approach that entails collecting clinical information and imaging to visualize inflammation or post-inflammatory changes of the axial skeleton. @RheumNow
      RT @MeralElRamahiMD: #Eular2021: Do you start a bDMARD for nr-AxSpa without objective evidence of inflammation (elevated

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years 5 months ago
      #Eular2021: Do you start a bDMARD for nr-AxSpa without objective evidence of inflammation (elevated CRP, negative structural damage on MRI)? @RheumNow
      RT @MeralElRamahiMD: #Eular2021 "Just because they do not have nonradiographic-AxSpa, it does not mean that the disease

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years 5 months ago
      #Eular2021 "Just because they do not have nonradiographic-AxSpa, it does not mean that the disease burden is less (compared to radiographic-AxSpa)!" Dr. Atul Deodhar @RheumNow
      RT @Stiddyo: Crosssectional multicentre study clusters phenotypes of #spondyloarthritis differentiating two types: axial

      Paul Studenic Stiddyo

      4 years 5 months ago
      Crosssectional multicentre study clusters phenotypes of #spondyloarthritis differentiating two types: axial and peripheral, Fitted well to either diagnoses of ax-SpA or #PsA. Still overlap of features like arthritis, dactylitis and enthesitis exists. #OP0047 #EULAR2021 @RheumNow https://t.co/sru9bT4mla

      Catch up on Conference Podcasts

      ×